Yahoo Web Search

Search results

1. finance.yahoo.com › news › harpoon-therapeuticsHarpoon Therapeutics Announces Up to $150 Million Private ...

   finance.yahoo.com › news › harpoon-therapeutics

   • Cached

   Oct 23, 2023 · SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell...

2. www.globenewswire.com › news-release › 2023/10/23Harpoon Therapeutics Announces Up to $150 Million Private

   www.globenewswire.com › news-release › 2023/10/23

   • Cached

   Oct 23, 2023 · SOUTH SAN FRANCISCO, Calif., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell...

3. www.harpoontx.comHarpoon Therapeutics | Immuno-oncology | TriTAC™

   www.harpoontx.com

   • Cached

   Dec 26, 2023 · Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline. December 26, 2023 Harpoon Therapeutics Strengthens Leadership Team. More News

4. www.merck.com › news › merck-to-acquire-harpoonMerck to Acquire Harpoon Therapeutics, Further Diversifying ...

   www.merck.com › news › merck-to-acquire-harpoon

   • Cached

   Jan 8, 2024 · Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology Pipeline. Acquisition includes HPN328, an investigational delta-like ligand 3 (DLL3) targeting T-cell engager being evaluated in certain patients with small cell lung cancer and neuroendocrine tumors.

5. www.globenewswire.com › news-release › 2023/03/27Harpoon Therapeutics Announces Closing of $25 Million

   www.globenewswire.com › news-release › 2023/03/27

   • Cached

   Mar 27, 2023 · SOUTH SAN FRANCISCO, Calif., March 27, 2023 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immuno-oncology company developing novel T cell...

6. www.nasdaq.com › articles › harpoon-therapeuticsHarpoon Therapeutics Announces Private Placement Of Up To ...

   www.nasdaq.com › articles › harpoon-therapeutics

   • Cached

   Oct 23, 2023 · (RTTNews) - Immunotherapy company Harpoon Therapeutics, Inc. (HARP) announced Monday that it has entered into a securities purchase agreement for a private placement in public equity (PIPE)...

7. People also ask

   What happened to harpoon Therapeutics?

   • SOUTH SAN FRANCISCO, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Harpoon Therapeutics, Inc. (Nasdaq: HARP), a clinical-stage immunotherapy company developing novel T cell engagers, today reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.

   Harpoon Therapeutics Reports Fourth Quarter and Full Year 2021 Finan…

   finance.yahoo.com/news/harpoon-therapeutics-reports-fourth-quarter-210400353.html

   See all results for this question

   What is harpoon Therapeutics?

   • About Harpoon Therapeutics Harpoon Therapeutics is a clinical-stage immunotherapy company developing a novel class of T-cell engagers designed to harness the power of the body’s immune system to treat patients suffering from cancer and other diseases.

   Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology

   www.merck.com/news/merck-to-acquire-harpoon-therapeutics-further-diversifying-oncology-pipeline/

   See all results for this question

   Which Harpoon products are in clinical trials?

   • Harpoon currently has several products in various stages of clinical trials, such as HPN328, which is in Phase I/II clinical trials for the treatment of small cell lung cancer and other Delta-like canonical Notch ligand 3-expressing tumors and HPN217, which is in Phase I/II clinical trials for the treatment of multiple myeloma.

   Harpoon Therapeutics (HARP) Stock Price, News & Analysis - MarketBeat

   www.marketbeat.com/stocks/NASDAQ/HARP/

   See all results for this question

   Will Merck buy Harpoon Therapeutics?

   • Under the terms of the agreement, Merck, through a subsidiary, will acquire all outstanding shares of Harpoon Therapeutics, Inc. for a price per share of $23.00 in cash. The Board of Directors of Harpoon has unanimously approved the transaction.

   Merck to Acquire Harpoon Therapeutics, Further Diversifying Oncology

   www.merck.com/news/merck-to-acquire-harpoon-therapeutics-further-diversifying-oncology-pipeline/

   See all results for this question

8. www.canaccordgenuity.com › capital-marketsHarpoon Therapeutics - Canaccord Genuity

   www.canaccordgenuity.com › capital-markets

   • Cached

   Canaccord Genuity is pleased to announce its client Harpoon Therapeutics, Inc. (NASDAQ: HARP) (the “Company”), a clinical-stage immunotherapy company developing novel T cell engagers, entered into a securities purchase agreement on October 23rd, 2023 for a private placement in public equity (“PIPE”) financing resulting in upfront gross ...